Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Shares Outstanding (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Shares Outstanding for 16 consecutive years, with $10.7 million as the latest value for Q1 2026.

  • Quarterly Shares Outstanding fell 50.46% to $10.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Jan 2026, down 50.46% year-over-year, with the annual reading at $21.7 million for FY2025, 0.0% changed from the prior year.
  • Shares Outstanding for Q1 2026 was $4766.0 at PharmaCyte Biotech, down from $7000.0 in the prior quarter.
  • The five-year high for Shares Outstanding was $21.7 million in Q1 2025, with the low at $4766.0 in Q1 2026.
  • Average Shares Outstanding over 5 years is $15.7 million, with a median of $21.6 million recorded in 2022.
  • The sharpest move saw Shares Outstanding plummeted 110.02% in 2022, then skyrocketed 92527.67% in 2025.
  • Over 5 years, Shares Outstanding stood at -$2.1 million in 2022, then surged by 101.52% to $31480.0 in 2023, then crashed by 81.27% to $5896.0 in 2024, then soared by 367472.85% to $21.7 million in 2025, then tumbled by 50.46% to $10.7 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $10.7 million, $21.7 million, and $21.7 million for Q1 2026, Q2 2025, and Q1 2025 respectively.